Welcome to our dedicated page for G1 Therapeutics news (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 3, 2023, at 8:30 a.m. ET, to provide a financial and corporate update for Q1 2023. The live event will discuss the company’s progress in developing COSELA® (trilaciclib), its first commercial product, and ongoing clinical trials across various solid tumors, including breast, lung, and bladder cancers. Participants are encouraged to register online to receive dial-in details, and a recorded version of the webcast will be available for 90 days post-event on the company's website. G1 Therapeutics continues to focus on advancing therapies that enhance patient outcomes in oncology.